ÖZET
Amaç:
İnce iğne aspirasyon biyopsisi (İİAB) ile tanısı doğrulanamayan ve ikinci bir invaziv işlem olarak cerrahi eksizyonel biyopsi (CEB) gerektiren hastalarda İİAB öncesi kaydedilen rutin kan değerleri ile kesin tanı arasındaki ilişkiyi değerlendirmektir.
Yöntem:
Bir araştırma hastanesinin kulak burun boğaz kliniğinde Mart 2014-Mart 2019 tarihleri arasında İİAB ile tanı konamayan ve servikal lenf nodu CEB yapılan hastaların verileri retrospektif olarak değerlendirildi. CEB’ye göre belirlenen kesin tanıya göre olgular şu şekilde 3 gruba ayrıldı: 1) benign, 2) diğer maligniteler, 3) lenfoma.
Bulgular:
Diğer maligniteler grubundaki erkeklerin sıklığı diğer iki gruba göre anlamlı olarak daha yüksekti (p=0,007). Diğer iki grupla karşılaştırıldığında, C-reaktif protein seviyeleri benign grupta istatistiksel olarak anlamlı düzeyde daha düşüktü (p=0,001). Lenfoma grubunda eritrosit sedimantasyon hızı (ESR) diğer gruplara göre anlamlı düzeyde daha yüksekti (p<0,001) ve lenfomayı diğer tümörlerden ayırmada ESR’nin >35,5 mm/saat kesim noktasında %70,21 duyarlılık, %75,76 özgüllük ve %73,97 doğruluğa sahip olduğu saptandı (eğri altındaki alan =0,784, %95 güven aralığı: 0,708-0,861, p<0,001).
Sonuç:
ESR, asemptomatik hastalarda lenfoma tanısı için spesifik olmasa da, tanı için servikal lenf nodu biyopsisine ihtiyaç duyan semptomatik hastalarda tekrarlayan invazif prosedürleri azaltmak için destekleyici bir belirteç olabilir.
References
1
Bispo JAB, Pinheiro PS, Kobetz EK. Epidemiology and etiology of leukemia and lymphoma. Cold Spring Harb Perspect Med 2020;10(6):a034819.
2
Chiu BC-H, Hou N. Epidemiology and etiology of non-hodgkin lymphoma. Non-Hodgkin Lymphoma: Springer, 2015:1-25.
3
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68(6):394-424.
4
Elinav E, Nowarski R, Thaiss CA, Hu B, Jin C, Flavell RA. Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer 2013;13(11):759-771.
5
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-674.
6
Hagerling C, Casbon A-J, Werb Z. Balancing the innate immune system in tumor development. Trends Cell Biol 2015;25(4):214-220.
7
Sagaert X, Van Cutsem E, De Hertogh G, Geboes K, Tousseyn T. Gastric MALT lymphoma: a model of chronic inflammation-induced tumor development. Nat Rev Gastroenterol Hepatol 2010;7(6):336-346.
8
Loong F, Chan AC, Ho BC, Chau YP, Lee HY, Cheuk W, et al. Diffuse large B-cell lymphoma associated with chronic inflammation as an incidental finding and new clinical scenarios. Mod Pathol 2010;23(4):493-501.
9
Makgoeng SB, Bolanos RS, Jeon CY, Weiss RE, Arah OA, Breen EC, et al. Markers of immune activation and inflammation and non-Hodgkin lymphoma: a meta-analysis of prospective studies. JNCI cancer spectrum 2018;2(4):pky082. doi: 10.1093/jncics/pky082.
10
Rotaru I, Gaman GD, Stanescu C, Gaman AM. Evaluation of parameters with potential prognosis impact in patients with primary gastric diffuse large B-cell lymphoma (PG-DLBCL). Rom J Morphol Embryol 2014;55(1):15-21.
11
Grivennikov SI, Greten FR, Karin M. Immunity, inflammation and cancer. Cell 2010;140(6):883-899.
12
Hamed Anber N, El-Sebaie AH, Darwish NH, Mousa SA, Shamaa SS. Prognostic value of some inflammatory markers in patients with lymphoma. Biosci Rep 2019;39(3):BSR20182174. doi: 10.1042/BSR20182174.
13
Wu S, Zhou Y, Hua H-Y, Zhang Y, Zhu W-Y, Wang Z-Q, et al. Inflammation marker ESR is effective in predicting outcome of diffuse large B-cell lymphoma. BMC Cancer 2018;18(1):997.
14
Tilly H, Gomes da Silva M, Vitolo U, Jack A, Meignan M, Lopez-Guillermo A, et al. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015;26(Suppl 5):v116-v125. doi: 10.1093/annonc/mdv304.
15
Dreyling M, Ghielmini M, Marcus R, Salles G, Vitolo U, Ladetto M. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014;25(Suppl 3):iii76-iii82.
16
Eichenauer DA, Engert A, André M, Federico M, Illidge T, Hutchings M, et al. Hodgkin’s lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014;25(Suppl 3):iii70-iii75. doi: 10.1093/annonc/mdu181.
17
Dreyling M, Campo E, Hermine O, Jerkeman M, Le Gouill S, Rule S, et al. Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017;28(Suppl 4):iv62-iv71. doi: 10.1093/annonc/mdx223.
18
Johl A, Lengfelder E, Hiddemann W, Klapper W, German Low-grade Lymphoma Study Group (GLSG). Core needle biopsies and surgical excision biopsies in the diagnosis of lymphoma-experience at the Lymph Node Registry Kiel. Ann Hematol 2016;95(8):1281-1286.
19
Okumura Y, Nomura K, Kikuchi T, Suzuki T, Hidaka H, Ogawa T, et al. Clinical factors indicating the presence of malignant lymphoma before lymph node dissection. Acta Otolaryngol 2015;135(5):513-518.
20
Bochen K, Krasowska A, Milaniuk S, Kulczynska M, Prystupa A, Dzida G. Erythrocyte sedimentation rate–an old marker with new applications. Journal of Pre-clinical and Clinical Research 2011;5(2):50-55.
21
Watson J, Salisbury C, Banks J, Whiting P, Hamilton W. Predictive value of inflammatory markers for cancer diagnosis in primary care: a prospective cohort study using electronic health records. Br J Cancer 2019;120(11):1045-1051.
22
Liu S, Ren J, Wu X, Ren H, Yan D, Wang G, et al. Preliminary case-control study to evaluate diagnostic values of C-reactive protein and erythrocyte sedimentation rate in differentiating active Crohn’s disease from intestinal lymphoma, intestinal tuberculosis and Behcet’s syndrome. Am J Med Sci 2013;346(6):467-472.
23
Alende-Castro V, Alonso-Sampedro M, Vazquez-Temprano N, Tuñez C, Rey D, García-Iglesias C, et al. Factors influencing erythrocyte sedimentation rate in adults: new evidence for an old test. Medicine (Baltimore) 2019;98(34):e16816.
24
Sproston NR, Ashworth JJ. Role of C-reactive protein at sites of inflammation and infection. Front Immunol 2018;9:754.
25
Allin KH, Bojesen SE, Nordestgaard BG. Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer. J Clin Oncol 2009;27(13):2217-2224.
26
Allin KH, Nordestgaard BG. Elevated C-reactive protein in the diagnosis, prognosis and cause of cancer. Crit Rev Clin Lab Sci 2011;48(4):155-170.
27
Heikkilä K, Ebrahim S, Lawlor DA. A systematic review of the association between circulating concentrations of C reactive protein and cancer. J Epidemiol Community Health 2007;61(9):824-833.
28
Xu H-J, Ma Y, Deng F, Ju W-B, Sun X-Y, Wang H. The prognostic value of C-reactive protein/albumin ratio in human malignancies: an updated meta-analysis. Onco Targets Ther 2017;10:3059-3070.
29
Bień E, Balcerska A. [Clinical significance of erythrocyte sedimentation rate, C-reactive protein and serum lactate dehydrogenase levels in the diagnosis, prognosis and treatment monitoring of children suffering from cancer.] Med Wieku Rozwoj 2004;8(4 Pt 2):1081-1089.
30
Wieland A, Kerbl R, Berghold A, Schwinger W, Mann G, Urban C. C-reactive protein (CRP) as tumor marker in pediatric and adolescent patients with Hodgkin disease. Med Pediatr Oncol 2003;41(1):21-25.
31
Kawaguchi Y, Saito B, Nakata A, Matsui T, Sasaki Y, Shimada S, et al. Elevated C-reactive protein level is associated with poor prognosis in follicular lymphoma patients undergoing rituximab-containing chemotherapy. Int J Hematol 2020;112(3):341-348.
32
Troppan K, Schlick K, Deutsch A, Melchardt T, Egle A, Stojakovic T, et al. C-reactive protein level is a prognostic indicator for survival and improves the predictive ability of the R-IPI score in diffuse large B-cell lymphoma patients. Br J Cancer 2014;111(1):55-60.
33
Li Y-J, Li Z-M, Xia Y, Huang J-J, Huang H-Q, Xia Z-J, et al. Serum C-reactive protein (CRP) as a simple and independent prognostic factor in extranodal natural killer/T-cell lymphoma, nasal type. PloS One 2013;8(5):e64158.
34
Du J, Wang Q, He B, Liu P, Chen JY, Quan H, et al. Association of mean platelet volume and platelet count with the development and prognosis of ischemic and hemorrhagic stroke. Int J Lab Hematol 2016;38(3):233-239.
